Stemline Therapeutics Inc (NASDAQ:STML) Receives $25.00 Average PT from Analysts

Shares of Stemline Therapeutics Inc (NASDAQ:STML) have earned an average recommendation of “Buy” from the nine research firms that are presently covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $25.00.

Several equities research analysts have commented on the stock. BidaskClub upgraded shares of Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday. HC Wainwright reiterated a “buy” rating and issued a $35.00 price target on shares of Stemline Therapeutics in a research report on Monday, September 30th. ValuEngine cut shares of Stemline Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, September 11th. Cowen restated a “buy” rating on shares of Stemline Therapeutics in a report on Wednesday, September 18th. Finally, Wedbush upgraded Stemline Therapeutics from a “neutral” rating to an “outperform” rating in a report on Friday, August 2nd.

STML stock traded down $1.19 during trading on Tuesday, hitting $9.25. 2,655,100 shares of the company’s stock traded hands, compared to its average volume of 625,907. The company has a quick ratio of 4.57, a current ratio of 4.71 and a debt-to-equity ratio of 0.01. The stock has a fifty day moving average price of $9.85 and a two-hundred day moving average price of $12.94. Stemline Therapeutics has a 52 week low of $7.82 and a 52 week high of $18.22. The stock has a market capitalization of $486.37 million, a price-to-earnings ratio of -3.09 and a beta of 1.35.

Stemline Therapeutics (NASDAQ:STML) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.08. The business had revenue of $13.33 million during the quarter, compared to the consensus estimate of $13.40 million. As a group, equities research analysts expect that Stemline Therapeutics will post -1.99 EPS for the current fiscal year.

In other Stemline Therapeutics news, CEO Ivan Bergstein sold 35,010 shares of the business’s stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $14.73, for a total transaction of $515,697.30. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 13.10% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Rhenman & Partners Asset Management AB increased its holdings in shares of Stemline Therapeutics by 3.4% in the 3rd quarter. Rhenman & Partners Asset Management AB now owns 511,023 shares of the biopharmaceutical company’s stock valued at $5,320,000 after purchasing an additional 17,024 shares during the period. Candriam Luxembourg S.C.A. acquired a new position in shares of Stemline Therapeutics in the 2nd quarter valued at about $1,220,000. BlackRock Inc. increased its holdings in shares of Stemline Therapeutics by 16.6% in the 2nd quarter. BlackRock Inc. now owns 3,152,812 shares of the biopharmaceutical company’s stock valued at $48,301,000 after purchasing an additional 449,323 shares during the period. Vanguard Group Inc. increased its holdings in shares of Stemline Therapeutics by 14.0% in the 2nd quarter. Vanguard Group Inc. now owns 1,933,455 shares of the biopharmaceutical company’s stock valued at $29,620,000 after purchasing an additional 237,768 shares during the period. Finally, Virtus ETF Advisers LLC increased its holdings in shares of Stemline Therapeutics by 112.7% in the 2nd quarter. Virtus ETF Advisers LLC now owns 57,127 shares of the biopharmaceutical company’s stock valued at $875,000 after purchasing an additional 30,273 shares during the period. Hedge funds and other institutional investors own 83.00% of the company’s stock.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.

Featured Story: What is the significance of a dead cat bounce?

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.